Table 2.

Comparison of events after 9vHPV vaccine and after comparator vaccine populations in the Vaccine Safety Datalink, from October 4, 2015 (9vhpv vaccine) or January 1, 2007 (comparator vaccines) to January 2, 2021 (both 9vhpv and comparator vaccines).

Adverse event	Sex/age categorya	Number of 9vHPV doses	Number of events in the post-9vHPV risk period	Events in the post-9vHPV risk period per 100,000 9vHPV doses	Number of comparator vaccine doses	Number of events in the post-comparator vaccine risk period	Events in the post-comparator vaccine risk period per 100,000 comparator vaccine doses
GBSb	F 9–17 years	680,795	3	0.4	1,029,301	7	0.7
	F 18–26 years	287,775	0	0	824,030	8	1.0
	M 9–17 years	726,585	3	0.4	1,341,127	10	0.8
	M 18–26 years	140,634	0	0	619,551	7	1.1
	Overall	1,835,789	6	0.3	3,814,009	32	0.8
CIDPc	F 9–17 years	680,795	1	0.2	1,029,301	1	0.1
	F 18–26 years	287,775	1	0.4	824,030	0	0
	M 9–17 years	726,585	0	0	1,341,127	0	0
	M 18–26 years	140,634	0	0	619,551	1	0.2
	Overall	1,835,789	2	0.1	3,814,009	2	0.1
Stroke	F 9–17 years	680,795	4	0.6	1,029,301	7	0.7
	F 18–26 years	287,775	14	4.9	824,030	30	3.6
	M 9–17 years	726,585	1	0.1	1,341,127	15	1.1
	M 18–26 years	140,634	3	2.1	619,551	26	4.2
	Overall	1,835,789	22	1.2	3,814,009	78	2.1

^aF: Females. M: Males.

^bGuillain-Barré syndrome.

^cChronic inflammatory demyelinating polyneuropathy.